ClinicalTrials.gg

Program

bleximenib

Also written as “Bleximenib”, “14C-bleximenib” and “JNJ-75276617”.

Its studies are mostly in Leukemia, Myeloid, Acute · Precursor Cell Lymphoblastic Leukemia-Lymphoma, led by Johnson & Johnson.

Furthest: phase 3, since Feb 25, 20254 company-led studies, 2 open or runningNext primary completion: Dec 29, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson42 open or runningphase 3since Feb 25, 2025Mar 22, 2021Dec 29, 2028phase 2 · NCT04811560
  • Named in Johnson & Johnson’s own pipeline as bleximenib, phase 3, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 22, 2021First study: phase 2 study in Acute LeukemiaFirst studyNCT04811560 · 420 planned · United States, Australia, Belgium and more
  2. Aug 29, 2022Phase 1 study in Leukemia, Myeloid, AcuteNCT05521087
  3. Feb 25, 2025Phase 3 study in Leukemia, Myeloid, AcuteNCT06852222 · 600 planned · United States, Australia, Austria and more
  4. Dec 9, 2025Phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT07295951 · 6 enrolled · United Kingdom
  5. Nov 4, 2026Primary completion moved from 2027-02-26 to 2028-12-29Date moved laterphase 2 · +22 months · NCT04811560

Ahead

  1. Dec 29, 2028Primary completion: phase 2 study in Acute LeukemiaNCT04811560
  2. Jun 22, 2029Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT06852222

TargetBeta

“An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; mixed-lineage leukemia 1; MLL1; myeloid/lymphoid leukemia; histone-lysine N-methyltransferase 2A; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, blexime…”NCIt, read by Claude
“An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; mixed-lineage leukemia 1; MLL1; myeloid/lymphoid leukemia; histone-lysine N-methyltransferase 2A; KMT2A) proteins, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
revumenibruleSyndax Pharmaceuticalsphase 36

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07295951Precursor Cell Lymphoblastic Leukemia-Lymphoma · United Kingdom1CompletedJul 21, 20266
NCT06852222Leukemia, Myeloid, Acute · United States, Australia, Austria and more3RecruitingJun 22, 2029600
NCT05521087Leukemia, Myeloid, Acute1WithdrawnSep 11, 20260
NCT04811560Acute Leukemia · United States, Australia, Belgium and more2RecruitingDec 29, 2028420

How it is read

Names in the registry

  • “Bleximenib”, 2 entries
  • “14C-bleximenib”, 1 entry
  • “bleximenib”, 1 entry
  • “JNJ-75276617”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.